A detailed history of Sg Americas Securities, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 27,706 shares of AVXL stock, worth $239,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,706
Previous 13,434 106.24%
Holding current value
$239,102
Previous $57,000 175.44%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$4.11 - $7.04 $58,657 - $100,474
14,272 Added 106.24%
27,706 $157,000
Q2 2024

Jul 12, 2024

BUY
$3.39 - $5.02 $45,541 - $67,438
13,434 New
13,434 $57,000
Q4 2023

Jan 12, 2024

BUY
$5.04 - $9.95 $192,301 - $379,642
38,155 Added 14.16%
307,568 $2.86 Million
Q3 2023

Oct 13, 2023

BUY
$6.55 - $9.37 $1.76 Million - $2.52 Million
269,413 New
269,413 $1.77 Million
Q1 2023

Apr 28, 2023

BUY
$8.32 - $11.75 $119,050 - $168,130
14,309 Added 83.81%
31,382 $269,000
Q4 2022

Feb 02, 2023

BUY
$7.65 - $14.43 $20,004 - $37,734
2,615 Added 18.09%
17,073 $158,000
Q3 2022

Oct 31, 2022

SELL
$8.9 - $12.86 $169,420 - $244,802
-19,036 Reduced 56.83%
14,458 $149,000
Q2 2022

Jul 29, 2022

BUY
$7.31 - $12.84 $244,841 - $430,062
33,494 New
33,494 $335,000
Q1 2022

Apr 29, 2022

SELL
$9.74 - $17.69 $122,237 - $222,009
-12,550 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$16.88 - $23.31 $213,633 - $295,011
-12,656 Reduced 50.21%
12,550 $218,000
Q3 2021

Nov 01, 2021

BUY
$16.82 - $25.75 $423,964 - $649,054
25,206 New
25,206 $452,000
Q2 2021

Aug 12, 2021

SELL
$10.16 - $28.86 $105,857 - $300,692
-10,419 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$5.17 - $16.13 $53,866 - $168,058
10,419 New
10,419 $156,000
Q1 2018

May 03, 2018

SELL
$2.32 - $3.44 $49,622 - $73,578
-21,389 Closed
0 $0
Q4 2017

Jan 24, 2018

BUY
$3.12 - $4.94 $66,733 - $105,661
21,389
21,389 $69,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.